J. Randolph Hecht, MD, UCLA Santa Monica Medical Center, Santa Monica, CA, discusses immunotherapy approaches in solid tumors, including tumor vaccines as well as CAR T-cell therapies. In the vaccine field, targeting KRAS is an area of ongoing interest and has been shown to elicit an immune response. In addition, Prof. Hecht touches on CAR T-cell therapies in solid tumors and associated challenges including efficacy and approaches to mitigate off-target toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
